Edition:
United Kingdom

Global Blood Therapeutics Inc (GBT.OQ)

GBT.OQ on NASDAQ Stock Exchange Global Select Market

39.55USD
16 Jul 2018
Change (% chg)

-- (--)
Prev Close
$39.55
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
305,317
52-wk High
$68.05
52-wk Low
$24.05

Chart for

About

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD). The... (more)

Overall

Beta: --
Market Cap(Mil.): $1,412.94
Shares Outstanding(Mil.): 43.68
Dividend: --
Yield (%): --

Financials

  GBT.OQ Industry Sector
P/E (TTM): -- 85.48 32.76
EPS (TTM): -2.47 -- --
ROI: -37.53 2.29 14.61
ROE: -37.85 3.86 16.34

GBT's drug meets trial goal, investors skeptical of speedy approval

Global Blood Therapeutics Inc's sickle cell disease treatment met the main goal of a late-stage trial, but scepticism over whether the drug would get an accelerated review from health regulators pushed its shares down 12 percent.

27 Jun 2018

UPDATE 3-GBT's drug meets trial goal, investors skeptical of speedy approval

* Shares fall as much as 12 pct (Adds details from conference call, analyst comments; updates share move)

27 Jun 2018

Global Blood Therapeutics' sickle cell disease drug succeeds in trial

June 27 Global Blood Therapeutics Inc said on Wednesday its experimental drug met the main goal of a late-stage trial testing it in patients with sickle cell disease.

27 Jun 2018

BRIEF-GBT Q1 Loss Per Share $0.87

* GBT REPORTS RECENT BUSINESS PROGRESS AND FIRST QUARTER 2018 FINANCIAL RESULTS

07 May 2018

BRIEF-Global Blood Therapeutics ‍priced underwritten public offering of 4.0 mln shares of its common stock

* GLOBAL BLOOD THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF 4,000,000 SHARES OF COMMON STOCK

09 Mar 2018

BRIEF-Global Blood Therapeutics Announces Proposed Public Offering

* GLOBAL BLOOD THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

08 Mar 2018

BRIEF-GBT Appoints David Johnson As Chief Commercial Officer

* GBT APPOINTS INDUSTRY LEADER DAVID L. JOHNSON AS CHIEF COMMERCIAL OFFICER Source text for Eikon: Further company coverage:

06 Mar 2018

BRIEF-Global Blood Therapeutics Q4 Loss Per Share $0.94

* GBT REPORTS RECENT BUSINESS PROGRESS AND FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS

27 Feb 2018

Competitors

Earnings vs. Estimates